Preeclampsia is a pregnancy-specific multisystem disorder, complicating 2-8% of pregnancies, and represents a leading cause of maternal and perinatal morbidity and mortality. Recent investigations have elucidated the understanding of its underlying pathogenic mechanisms. However, despite these advances, therapeutic approaches are still severely limited. Ongoing lines of research indicate some potential novel therapeutic options, targeting the etiopathogenic pathways and, thus, offering hope for effective pharmacologic interventions to be available in the near future. In this editorial, we will give an updated overview of Preeclampsia pathogenesis and promising emerging therapeutic options. © 2014 Informa UK Ltd
Ornaghi, S., Paidas, M. (2014). Upcoming drugs for the treatment of preeclampsia in pregnant women. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 7(5), 599-603 [10.1586/17512433.2014.944501].
Upcoming drugs for the treatment of preeclampsia in pregnant women
ORNAGHI, SARAPrimo
;
2014
Abstract
Preeclampsia is a pregnancy-specific multisystem disorder, complicating 2-8% of pregnancies, and represents a leading cause of maternal and perinatal morbidity and mortality. Recent investigations have elucidated the understanding of its underlying pathogenic mechanisms. However, despite these advances, therapeutic approaches are still severely limited. Ongoing lines of research indicate some potential novel therapeutic options, targeting the etiopathogenic pathways and, thus, offering hope for effective pharmacologic interventions to be available in the near future. In this editorial, we will give an updated overview of Preeclampsia pathogenesis and promising emerging therapeutic options. © 2014 Informa UK LtdI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.